Arachidonic acid metabolic pathway has remarkable contribution in the working of biological systems. Having arachidonic acid as the common substrate; the COX-1, COX-2 and 5-LOX channels of this metabolic pathway produce different metabolites which play a significant role in homeostasis, blood clotting, gastrointestinal protection, inflammation and vasoconstriction. The quantity of metabolite produced from the three channels depends upon the expression of each enzyme as well as the affinity of the enzymes for arachidonic acid (the substrate). Here, it is found that the relative affinity of the three enzymes for AA follows the order 5-LOX, COX-1 and COX-2. Based on this trend, the metabolic significance of each channel is rationalized. Moreover, examining the relative interactions of anti-inflammatory drugs like aspirin, diclofenac, indomethacin, celecoxib, zileuton with the three enzymes, the possibility of side effects associated with these drugs was also revisited.
INTRODUCTION
Understanding the mode of working of various enzymes of arachidonic acid (AA) metabolic pathway was a milestone towards the systematic practice of chemotherapy of inflammatory diseases. It has also helped in disclosing the mechanism of action and side effects of antiinflammatory drugs [1] [2] [3] [4] [5] . Under the normal physiological conditions, the housekeeping enzyme cyclooxygenase-1 (COX-1) metabolizes AA for production of prostaglandins (PGs) which help in blood clotting, homeostasis and gastrointestinal protection. During inflammatory conditions, the inducible enzyme cyclooxygenase-2 (COX-2) makes prostaglandins from AA which cause pain, fever and heart problems while 5-lipoxygenase (5-LOX) channel of AA pathway metabolizes AA to generate vasoconstrictive leukotrienes responsible for BRIEF REPORT cardiovascular diseases [6, 7] . AA being the substrate of three enzymes viz. COX-1, COX-2 and lipoxygenase, the fate and consequences of AA metabolism depend upon its availability to each one of the three enzymes. If excess of AA produced under inflammatory conditions is metabolized by COX-1, there could be no or less production of inflammatory prostaglandins coming from COX-2/5-LOX channel and this might be the natural way to get rid of acute/chronic inflammation. Moreover, the relative affinity of AA for these three enzymes could be a deciding factor in shunting of AA metabolism to either COX-1 or 5-LOX and COX-1 or COX-2 channel in case of inhibition of COX-2 and 5-LOX, respectively during the chemotherapy of inflammatory diseases.
Therefore, addressing a fundamental issue of AA pathway, the present work was focused to explore (i) whether AA is equally available to COX-1, COX-2 and 5-LOX or the three enzymes have different affinity for their common substrate and (ii) the comparison of affinity of some known anti-inflammatory drugs and AA for the three enzymes. Results of these studies will help (i) to know the Nature's management for the working of COX-1, COX-2 and lipoxygenase channels of AA metabolism so as to evade maximum possible stress caused under inflammatory conditions, (ii) to understand redistribution of AA when one of the three enzymes is blocked (using enzyme inhibitors for inflammation treatment) and (iii) in designing and development of new anti-inflammatory drugs. Since the stoichiometry and magnitude of association constant of a complex is indicative of affinity and strength of interaction between the two species [8] , these two parameters of AA/drug -enzyme complex were determined. Electrospray ionization (ESI) mode of mass spectrometry [9] [10] [11] [12] [13] [14] [15] was advantageously used for studying the interaction/complexation of AA/drug with COX-1, COX-2 and 5-LOX.
MATERIALS AND METHODS
Solutions of 11.0, 11.0 and 15.36 µM concentration (ACN-H2O, 7:3, 10 mM ammonium acetate) (concentration of the enzyme calculated from UV spectra) of COX-1, COX-2 and 5-LOX, respectively were prepared for recording mass spectra. Same solvent system was used for preparing solutions of AA and the drugs. Mass spectra were recorded on microTOF QII Bruker mass spectrometer operating in +ve ESI mode with source temperature 180 o C and using N2 as nebulizer gas. Since enzyme is much larger in size in comparison to the guest (drug) molecule, it is expected that depending upon the affinity of the guest for the enzyme, more than one guest molecules may interact with the enzyme. The stoichiometry of the enzyme-ligand (E:L) complex was calculated from the difference in the mass of EL complex and pure enzyme divided by the mass of the ligand while the association constants were calculated using equation 1. 
RESULTS AND DISCUSSION
Mass spectra of COX-1, COX-2 and 5-LOX and solutions of COX-1, AA; COX-2, AA and 5-LOX, AA were recorded. The solutions of COX-1-AA, COX-2-AA and 5-LOX-AA showed additive mass peaks ( Figure 1 ) when 20 µM concentration of AA was used but the stoichiometry and association constants in the three cases were different. The stoichiometries of COX-1-AA complex (1:11) and 5-LOX-AA (1:10) complex were comparative while for COX-2-AA complex, it was found to be 1:2 ( Table 1 ). The association constants of AA with COX-1, COX-2 and 5-LOX (Table 2) , as calculated from the mass spectral data indicated significantly higher association of AA and 5-LOX (Ka 0.76x10 4 M -1 ) in comparison to the association of AA with COX-1 (Ka 0.39x10 4 M -1 ) and COX-2 (Ka 0.18x10 4 M -1 ). To see the effect of AA concentration on its association with the enzymes, mass spectra of solutions of AA with the three enzymes at higher concentration of AA (40, 60 and 80 µM) were also recorded. Stoichiometries of AA with the three enzymes were same as observed with 20 µM concentration of AA (Table 1) .
Therefore, it was quite apparent from the results of these studies that out of the three enzymes, AA has more affinity for 5-LOX and COX-1, so to produce the prostaglandins continuously needed for housekeeping functions. Out of COX-1 and 5-LOX, AA showed preference for 5-LOX over COX-1 as the association constant of 5-LOX-AA is higher than that of COX-1-AA. It seems that at higher concentration of AA only, the COX-2 channel is switched on and creates acute inflammatory conditions. However, even at higher concentration of AA, it is more available to COX-1 and 5-LOX (higher EL stoichiometry) followed by its availability to COX-2 indicating the beauty of natural system that production of inflammatory prostaglandins is the last choice of the Nature. These results were exaggerated by examining the preference of AA for COX-1, COX-2 and 5-LOX from a mixture of these enzymes. Mass spectra of solutions containing AA, COX-1, COX-2; AA, COX-1, 5-LOX; AA, COX-2, 5-LOX and AA, COX-1, COX-2, 5-LOX (Entries 1-4, Table 3 ) were recorded. The results of the mass spectra of these four solutions have clearly shown the preference of AA for COX-1 in a mixture of COX-1 and COX-2 and preference for 5-LOX from mixture of COX-1 and 5-LOX. Similarly, AA preferred 5-LOX from a mixture of COX-2 and 5-LOX while AA was found in complexation with both COX-1 and 5-LOX in a mixture of COX-1, COX-2 and 5-LOX (Figure 2) . Noticeably, these The thermodynamic stability of the complexes of AA with 5-LOX, COX-1 and COX-2 enzymes, as calculated from equation 2 was found to be -7.61, -6.43 and -5.83 kcal/mol, respectively. This data also supported the above trend of preference of AA for the three enzymes. ∆Go = -RT lnka (2) The lessons conveyed from exploring this strategically managed differential availability of AA to the three enzymes are: (i) Nature does its maximum possible efforts to dispose of AA through COX-1 and 5-LOX channels by the production of bio-friendly PGs, and AA is lastly subjected to COX-2 when its concentration might crosses certain limit, (ii) For studying the side effects of antiinflammatory drugs and for designing more such drugs, the association constants and stoichiometries of compounds with COX-1, COX-2 and 5-LOX and their comparison with that of AA must act as pathfinders.
Encouraged by the information available from the above experiments, it was planned to study some clinically used anti-inflammatory drugs for their behavior towards AA metabolism and intensity of side effects associated with these drugs. The stoichiometry and association constants of aspirin, indomethacin, diclofenac, celecoxib, and zileuton with COX-1, COX-2 and 5-LOX were studied and compared with that of AA. The choice of these drugs was based upon the COX-1/2 non-selective [16] behavior of first three, COX-2 selective mode of action of celecoxib [17] and 5-LOX selectivity of zileuton. [18] Mass spectra of the respective solutions of these drugs with COX-1, COX-2 and 5-LOX were recorded. As evident from the stoichiometry and association constant data of aspirin with COX-1 and COX-2 (entries 6-9, Table 1; entry 2, Table 2 ), its affinity as well as association constants for COX-1 and COX-2 are higher than that of AA (Figure 4 ).
The stoichiometry of COX-1-aspirin complex was 1:14 which is slightly higher than that observed for COX-1-AA and almost 7 times the stoichiometry of COX-2-AA complex. Likewise, 0.93 x 10 4 M -1 and 0.22 x 10 4 M -1 as the respective association constants of COX-1-aspirin and COX-2-aspirin are better than the association constants of AA with these two enzymes. Interestingly, aspirin did not show association with 5-LOX at any of the four tested concentrations.
Hence, as expected, the experimental observations are in favor of the fact that aspirin is capable to replace AA from COX-2 and brings immediate relief from pain and inflammation. But at the same time, aspirin is also blocking COX-1 by replacing the natural substrate of COX-1 leading to various side effects. This was also checked by competitive binding of aspirin and AA with COX-1 and COX-2. Mass spectra of the two solutions containing COX-1, AA, aspirin and COX-2, AA, aspirin were recorded. Both the spectra showed peaks at m/z 73666 and 70729 corresponding to additive mass of COX-1 -aspirin and COX-2 -aspirin, respectively (entries 5, 8, Table 3 ; Figure  5 ) which clearly indicated that in comparison to AA, aspirin has higher affinity for these two enzymes. Intriguingly, the results obtained during the studies of diclofenac and indomethacin with COX-1, COX-2 and 5-LOX clearly differentiates the efficacy and side effects of these two drugs from aspirin. In comparison to aspirin, both diclofenac and indomethacin showed better stoichiometry and association constants with COX-2 indicating their higher potency as anti-inflammatory drugs (entries 10-17, Table 1 ; entries 3-4, Table 2 ). Moreover, in comparison to aspirin; diclofenac and indomethacin exhibited lower stoichiometry and association constants with COX-1 evidencing their weaker side effects (due to less inhibition of COX-1 channel). Mass spectra of solutions of COX-1 -AA -diclofenac; COX-1 -AA -indomethacin; COX-2 -AA -diclofenac and COX-2 -AA -indomethacin showed peaks at m/z corresponding to the additive mass of COX-1-AA, COX-1-AA, COX-2-diclofenac and COX-2-indomethacin, respectively (entries 6,7, 9 and 10, Table 3 ). These competitive experiments clearly indicated that in mixture of AA, diclofenac/indomethacin and COX-1; AA showed preferential binding with COX-1 while in mixture of AA, diclofenac/indomethacin and COX-2; diclofenac/indomethacin exhibited preferential binding with COX-2. Similar to aspirin; diclofenac and indomethacin too did not interact with 5-LOX. However, the inhibition of both COX-1 and COX-2 channel by aspirin and diclofenac may shunt the AA metabolism to the 5-LOX channel. Hence, side effects of aspirin and diclofenac, due to the more production of leukotrienes through 5-LOX channel, are expected.
However, celecoxib did not show additive mass with COX-1 and 5-LOX at any of the four tested concentrations but found to exhibit great affinity for COX-2 (entries 18-21, Table 1; entry 5, Table 2 ). Ka for celecoxib-COX-2 viz. 2.15 x 10 4 M -1 was much better than that of AA-COX-2 and hence, a potent and selective inhibitor of COX-2. To see if the blockage of COX-2 channel of AA metabolism through the use of COX-2 inhibitors makes the AA available to COX-1 or 5-LOX, mass spectrum of a solution of COX-1, COX-2, 5-LOX, AA and celecoxib was recorded (entries 12-14, Table 3 ). Three mass peaks corresponding to the additive mass of COX-2 + celecoxib, COX-1 + AA and 5-LOX + AA supported the earlier observations that blockage of COX-2 makes the AA available to COX-1 as well as 5-LOX. The observations and inferences of table 3 support the data shown in table 1 and clearly indicated the preference of AA for 5-LOX followed by COX-1 and COX-2. Hence, the use of COX-2 selective inhibitors as anti-inflammatory drugs may not immediately lead to 5-LOX mediated toxic effects, rather COX-1 channel also tries to dispose of excess AA. Similar to the selectivity of celecoxib for COX-2, zileuton was found to be highly selective for 5-LOX. Mass spectra of zileuton in separate combinations of COX-1, COX-2 and 5-LOX showed zileuton-enzyme additive mass spectral peak only with 5-LOX (entries 22-25, Table 1 ) and found to exhibit 5-LOXzileuton stoichiometry 1:10 (similar to that of 5-LOX-AA) and Ka 0.26 x 10 4 M -1 (entry 6, Table 2 ).
Therefore, the mass spectral investigations provided a quick and accurate comparison of the affinity of AA and various anti-inflammatory drugs for COX-1, COX-2 and 5-LOX enzymes. Being a common substrate of COX-1, COX-2 and 5-LOX; AA has preference for 5-LOX followed by COX-1 and COX-2. The competitive experiments indicate that AA preferred COX-1 from a mixture of COX-1, COX-2 and preferred 5-LOX from a mixture of COX-1, 5-LOX. This trend is clearly indicative of the fact that Nature has devised its own mechanism to get rid of inflammatory conditions by disposing of maximum AA (produced during inflammatory conditions) through COX-1, 5-LOX channel. As per the observations from these experiments, an effective and safe antiinflammatory drug must exhibit (i) binding constant with COX-2 higher than that of AA with COX-2, (ii) lower association with COX-1 than that of AA for COX-1, (iii) appreciable inhibition of 5-LOX too so that during the inhibition of COX-2 channel, 5-LOX may not produce leukotrienes more than its normal limit.
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